AR039628A2 - Formulacion masticable de carprofeno, implante y composicion terapeutica - Google Patents

Formulacion masticable de carprofeno, implante y composicion terapeutica

Info

Publication number
AR039628A2
AR039628A2 ARP030101251A ARP030101251A AR039628A2 AR 039628 A2 AR039628 A2 AR 039628A2 AR P030101251 A ARP030101251 A AR P030101251A AR P030101251 A ARP030101251 A AR P030101251A AR 039628 A2 AR039628 A2 AR 039628A2
Authority
AR
Argentina
Prior art keywords
alkyl
phenyl
implant
formulation
carprophene
Prior art date
Application number
ARP030101251A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR039628A2 publication Critical patent/AR039628A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación masticable, un implante y una composición que comprenden carprofeno. Una composición caracterizada porque comprende una cantidad terapéuticamente efectiva de un compuesto de fórmula (1), en la que, R2 es -(CXY)n-C(O)-A, donde A es hidroxi, alcoxi (C1-4), amino, hidroxiamino, mono-alquilamino(C1-2), di-alquilamino(C1-2); X e Y son, independientemente, H o alquilo(C1-2); y n es 1 ó 2; R6 es halógeno, alquilo (C1-3), trifluorometilo o nitro; R9 es H; alquilo(C1-2); fenilo o fenil-alquilo(C1-2), donde el fenilo está opcionalmente mono-sustituido con fluoro o cloro; -C(=O)-R, donde R es alquilo(C1-2) o fenilo, opcionalmente mono-sustituido con fluoro o cloro; o -C(=O)-O-R1, donde R1 es alquilo(C1-2); donde X e Y son diferentes, los enantiómeros (-)(R) y (+)(S) de los mismos; y todas las formas de sales farmacéuticamente aceptables, profármacos y metabolitos de los mismos, en una forma de dosificación controlada que sea capaz de mantener los niveles de plasma por sobre aproximadamente 10 micro g/ml durante un período mayor a 10,5 horas. Estos son útiles en el tratamiento del dolor y de la inflamación con una menor incidencia de efectos secundarios.
ARP030101251A 1997-05-05 2003-04-09 Formulacion masticable de carprofeno, implante y composicion terapeutica AR039628A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4563597P 1997-05-05 1997-05-05

Publications (1)

Publication Number Publication Date
AR039628A2 true AR039628A2 (es) 2005-03-02

Family

ID=21939053

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102089A AR011726A1 (es) 1997-05-05 1998-05-05 Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento
ARP030101251A AR039628A2 (es) 1997-05-05 2003-04-09 Formulacion masticable de carprofeno, implante y composicion terapeutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980102089A AR011726A1 (es) 1997-05-05 1998-05-05 Procedimiento para el tratamiento o prevencion del dolor y procesos y enfermedades inflamatorias, composicion farmaceutica, envase para uso en elmercado en dicho procedimiento

Country Status (32)

Country Link
EP (1) EP0988034A1 (es)
JP (1) JP2000513020A (es)
KR (2) KR20040004406A (es)
CN (1) CN1255059A (es)
AP (1) AP9801234A0 (es)
AR (2) AR011726A1 (es)
AU (1) AU6932198A (es)
BG (1) BG103852A (es)
BR (1) BR9808720A (es)
CA (1) CA2288759A1 (es)
DZ (1) DZ2479A1 (es)
EA (1) EA003696B1 (es)
GT (1) GT199800063A (es)
HR (1) HRP980244A2 (es)
HU (1) HUP0001286A3 (es)
ID (1) ID21311A (es)
IL (1) IL132570A0 (es)
IS (1) IS5220A (es)
MA (1) MA26491A1 (es)
NO (1) NO995389L (es)
NZ (1) NZ500183A (es)
OA (1) OA11213A (es)
PA (1) PA8450601A1 (es)
PE (1) PE72599A1 (es)
PL (1) PL337003A1 (es)
SK (1) SK148199A3 (es)
TN (1) TNSN98059A1 (es)
TW (1) TW590773B (es)
UY (1) UY24989A1 (es)
WO (1) WO1998050033A1 (es)
YU (1) YU55899A (es)
ZA (1) ZA983722B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245797B1 (en) 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
AU2003204888B2 (en) * 1998-05-22 2005-07-28 Pfizer Products Inc. Treating or Preventing the Early Stages of Degeneration of Articular Cartilage or Subchondral Bone in Mammals Using Carprofen and Derivatives
US6506785B2 (en) 1998-05-22 2003-01-14 Pfizer, Inc. Treating or preventing the early stages of degeneration of articular cartilage or subchondral bone in mammals using carprofen and derivatives
AU764872B2 (en) * 1998-10-23 2003-09-04 Merck Frosst Canada & Co. Combination product comprising an E-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
WO2000053149A2 (en) * 1999-03-10 2000-09-14 G.D. Searle & Co. Method and composition for administering a cyclooxygenase-2 inhibitor
WO2001034204A1 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2004521856A (ja) * 2000-05-15 2004-07-22 メルク フロスト カナダ アンド カンパニー Cox−2選択的阻害剤およびトロンボキサン阻害剤を用いる併用療法ならびにそのための組成物
RU2003100874A (ru) 2000-06-13 2004-06-27 Вайс (Us) Болеутоляющие и противовоспалительные составы, содержащие ингибиторы циклооксигеназы-2
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
US7189504B2 (en) 2000-08-07 2007-03-13 Vanderbilt University Compositions and methods for detecting and quantifying COX-2 activity and 2-arachidonylglycerol metabolites
US20040209959A1 (en) * 2001-07-16 2004-10-21 Edward Hogestatt Congeners of acetaminophen and related compounds as substrates for fatty acid conjugation and their use in treatment of pain, fever and inflammation
CA2519189C (en) 2003-05-07 2012-07-17 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
KR100780983B1 (ko) * 2003-07-31 2007-11-30 파마시아 앤드 업존 캄파니 엘엘씨 소염제의 분산성 제제
WO2006123247A2 (en) * 2005-05-20 2006-11-23 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
WO2008122967A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited An oral pharmaceutical composition
WO2008132707A1 (en) 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
EP2464341B1 (en) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
DK3113774T3 (da) 2014-03-06 2022-03-07 Elanco Animal Health Incorporated Sammensætninger af grapiprant og fremgangsmåder til anvendelse deraf
EA036036B1 (ru) 2014-11-07 2020-09-16 Сигмойд Фарма Лимитед Композиции, содержащие циклоспорин
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
MX2017009011A (es) * 2015-01-09 2017-10-02 Jaguar Animal Health Metodos para tratar la diarrea en animales de compañia.
JP2023520367A (ja) * 2020-03-25 2023-05-17 エスアールアイ インターナショナル リポキシゲナーゼ阻害剤
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (ko) 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions

Also Published As

Publication number Publication date
SK148199A3 (en) 2001-09-11
HRP980244A2 (en) 1999-02-28
JP2000513020A (ja) 2000-10-03
YU55899A (sh) 2003-08-29
HUP0001286A3 (en) 2000-12-28
KR20040004406A (ko) 2004-01-13
EA003696B1 (ru) 2003-08-28
BR9808720A (pt) 2000-07-11
PE72599A1 (es) 1999-08-12
NZ500183A (en) 2002-04-26
UY24989A1 (es) 2001-10-25
TNSN98059A1 (fr) 2005-03-15
CA2288759A1 (en) 1998-11-12
KR20010012300A (ko) 2001-02-15
EP0988034A1 (en) 2000-03-29
AR011726A1 (es) 2000-08-30
HUP0001286A2 (hu) 2000-11-28
IL132570A0 (en) 2001-03-19
ZA983722B (en) 1999-11-04
EA199900895A1 (ru) 2000-06-26
GT199800063A (es) 1999-10-26
WO1998050033A1 (en) 1998-11-12
AU6932198A (en) 1998-11-27
OA11213A (en) 2003-07-14
PA8450601A1 (es) 2000-05-24
PL337003A1 (en) 2000-07-31
DZ2479A1 (fr) 2003-02-01
AP9801234A0 (en) 1999-11-04
TW590773B (en) 2004-06-11
NO995389D0 (no) 1999-11-04
MA26491A1 (fr) 2004-12-20
ID21311A (id) 1999-05-20
IS5220A (is) 1999-10-19
BG103852A (en) 2000-06-30
CN1255059A (zh) 2000-05-31
NO995389L (no) 2000-01-04

Similar Documents

Publication Publication Date Title
AR039628A2 (es) Formulacion masticable de carprofeno, implante y composicion terapeutica
AR013477A1 (es) Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp.
DK0524587T3 (da) Terapeutiske sammensætninger til intranasal indgivelse indeholdende Ketorolac R
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
AR012014A1 (es) Composiciones para tratamiento de un dia de enfermedades mediadas por ciclooxigenasa-2
RU97117350A (ru) Ингибитор гипертрофии интимы, применение оксиндолового производного для получения ингибитора гипертрофии интимы, композиция для ингибирования гипертрофии интимы, способ предупреждения и лечения гипертрофии интимы
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
MY106552A (en) Novel pyrido[2,3-f] [1,4]thiazepines and pyrido[3,2-b] [1,5] benzothiazepines.
DE60003194D1 (de) Sedativ hypnotische zusammensetzungen mit gesteuerter freisetzung und diesbezügliche verfahren
NO964216L (no) Ester- og karbamatderivater av azoloner som er kraftige midler mot Helicobacter
CO5271694A1 (es) Inhibidores beta di-sustituidos de las metaloproteasas, composiciones farmaceuticas que los contienen y procedimientos para su aplicacion
SE9900190D0 (sv) New compounds
PE20050139A1 (es) Compuestos derivados de acidos hidroxamicos y composiciones farmaceuticas
NO171363C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive oksysalicylaminoderivater
IT1244696B (it) Derivato chinolonico ad attivita' antibatterica e mucolitica
SE8003246L (sv) Nytt antihypertensivt medel

Legal Events

Date Code Title Description
FB Suspension of granting procedure